2017 American Transplant Congress
Prevalence of CYP3A Genomic Variances and Impact on Tacrolimus Dosing Requirements in Kidney Transplant Recipients in Eastern North Carolina.
1Vidant Medical Center, Greenville, NC; 2East Carolina University, Greenville, NC
BACKGROUND: African American (AA) patients are substantially more likely to express CYP3A5. Presence of CYP3A5 polymorphisms is an important pharmacotherapeutic consideration due to the extensive…2017 American Transplant Congress
Immunosuppression (IS) Withdrawal (ISW) After ATG and Rituximab in Kidney Transplant Recipients (KTR): RESTARRT Early Results (NCT01318915).
Growing evidence implicates B cells in transplant tolerance. RESTARRT is a 6-center ISW study in adult living-related-donor KTR receiving ATG induction and rituximab with a…2017 American Transplant Congress
Personalized Tacrolimus (TAC) Dosing Using Genetic Variants in Caucasian Kidney Transplant (Tx) Recipients.
TAC is an immune suppressant with a narrow therapeutic index and high pharmacokinetic (PK) variability leading to uncertainty in blood concentrations. We previously developed an…2017 American Transplant Congress
Impact of Immunosuppression Adherence on De Novo Donor-Specific Antibody Formation in Renal Transplant Recipients in Canada: A Modeling Analysis.
Acute rejection rates and short-term graft survival have improved substantially as a result of advances in immunosuppression (IS), though longer-term graft survival rates have improved…2017 American Transplant Congress
Pre Transplant Donor Specific Antibodies and Clinical Outcomes in Kidney Transplant Recipient on Steroid Free Maintenance Immunosupression Regimen.
Background: The clinical relevance of pre transplant donor specific antibodies has been reported in few clinical studies with respect to its effect on the risk…2017 American Transplant Congress
Alemtuzumab Induction and Belatacept Maintenance in Marginal Pathology Renal Allografts.
University of Maryland, Baltimore
Background: The potential for improved outcomes with CNI avoidance may be important for kidneys with an increased likelihood of impaired graft function. We performed a…2017 American Transplant Congress
Renal Function Outcomes by HLA Mismatch in De Novo Kidney Transplant Recipients Receiving Everolimus PlusReduced-Dose Cyclosporine versus Mycophenolate Plus Standard-Dose Cyclosporine: 24-Month Subanalysis of A1202 Study.
Purpose: High levels of human leukocyte antigen (HLA) mismatches are a key determinant of kidney allograft survival. Here, we present 24-month (M) subanalysis of the…2017 American Transplant Congress
Effect of Everolimus-Based Regimen on Graft Outcomes in Kidney Transplant Recipients with Diabetes at Baseline: Post-Hoc Analysis from the ELEVATE Study.
1ELEVATE Study Group, Leiden, Netherlands; 2Novartis Pharma AG, Basel, Switzerland
Purpose: Presence of diabetes may have adverse impact on graft outcome in kidney transplant recipients (KTxRs). This post-hoc analysis from the ELEVATE study compared the…2017 American Transplant Congress
Benefits of Mycophenolate Sodium Over Mycophenolate Mofetil in Renal Transplant Patients Carrying UGT1A9 Polymorphism.
Nephrologist, Hospital Clínico San Carlos, Madrid, Spain
Aims: To analyze the differences in mycophenolic acid (MPA) pharmacokinetics and digestive side effects in renal transplant recipients on treatment with Mycophenolate mofetil (MMF) and…2017 American Transplant Congress
An Analysis of Tacrolimus XL Dosing in Obese Kidney Transplant Recipients.
Background:Tacrolimus extended-release (XL) is utilized in many immunosuppressive regimens post-kidney transplantation. Current dosing recommendation for the XL formulation in renal transplant (txp) is 0.15 mg/kg/day…
American Transplant Congress abstracts